CoiN a center of innovation for nanobiotechnology

799
-1

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
799
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
16
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

CoiN a center of innovation for nanobiotechnology

  1. 1. SRTTD July 30, 2010 Brooks Adams Executive Director & President Accelerating Commercialization in Nanobiotechnology
  2. 2. Outline 1. COIN 2. The opportunity 3. COIN’s role 4. Working together
  3. 3. We promote innovation & commercialization in nanobiotechnology & nanomedicine to enable future economic growth & improve human life. COIN
  4. 4. Key facts  Nonprofit 501c3 launched June 2009  $2.6 million funds committed  4 full-time staff  Outsource finance, marketing, & IT  University intern program (4 - 5)  8 Board members & 6 on SAB  Annual operating budget ~ $800K to 1MM  Based in Triangle; frequently in Triad & Charlotte and beyond
  5. 5. “Human health has always been determined on the nanometer scale…where the structure & properties of the machines of life work in every one of the cells in every living thing. The practical impact of nanosciences on human health will be huge.” Dr. Richard Smalley, Nobel Laureate The opportunity
  6. 6. Nanobiotechnology  Application of nanotechnology materials, tools, & processes in the life sciences & medicine:  Commercial applications:  Therapeutics & diagnostics  Medical technology & devices  Medical/life science research  Non human health-care related Versatile structure of carbon nanotubes enables use for variety of tasks in the body
  7. 7. The promise & challenge  Nanotech is a tool box not an industry  Many potential high value applications  Nanotech centers are forming globally & industry clusters grow around them  Requisite capabilities/resources:  Research, infrastructure, talent, money, & a conducive business environment are needed  A few major centers will develop “A Roadmap for Nanotechnology in NC’s 21st Century Economy,” March 2006
  8. 8. Nanobiotech global market  2009 nanomedicine healthcare market largest in N America at $4.75 billion followed by Europe at $3.65 billion  Nano-enabled drug delivery largest segment with expected CAGR of 21.7% to ~ $16 billion by 2014  Biocompatible implants & coatings and diagnostics estimated growth of 42% & 21.8%, respectively through 2014  Global clusters: US, Singapore, Canada, Australia, Germany, China, UK, & Israel  US hubs: Boston, San Francisco, Houston, & RTP  US academic centers of excellence: NC, Mass., California, Ohio, & Texas Sources: Business Insights (Jan 2010), Pew Charitable Trusts, COIN database
  9. 9. Nanomedicine patents 3% 3% 8% 14% 15% 57% Active Implants Drugs and Therapies Biomaterials Imaging In vitro Diagnostics Drug Delivery Provided by Wake Forest Univ. Center for Translational Nanomedicine .
  10. 10. Site-specific, targeted delivery Kam Leong, Duke University
  11. 11. Tissue engineering Kam Leong, Duke University
  12. 12. Vision for NC  Assets to succeed lie in Charlotte, Triad, & Triangle  Mix of nanotech research activity, medical centers, related large/emerging companies, and investors  To be nationally competitive, must promote projects in this corridor leveraging resident assets
  13. 13. NC nanobiotech ecosystem overview  Building from thriving, mature biotech industry & infrastructure, emerging nanobiotech sector is gaining rapid traction  NC strong in 3 of highest-growth nanotech sectors:  Medicine & healthcare  Tools/instruments  Materials  NC repeatedly recognized as leader in nanotech  2009 survey (PEN) ranked NC 8th in US & Raleigh metro area 4th  2009 US University Report & Rankings by Small Times placed NCSU 3rd in for nanotech commercialization and UNC-CH 5th & NCSU 10th for nanotech research  Positive political-business climate in support of biotech, low- cost of doing business, & high quality of life  NC Innovation Council
  14. 14. NC nanobiotech ecosystem overview  Industry  > 70 nanotech companies & 35 nanobiotech companies  > 280 US nanobiotech companies & additional 150 int’l nanobiotech companies  University & college resources  30 university research centers  Two nanotech PhD programs (only 36 in world)  Among 1st in nation to offer nanotech associates degree  Supportive infrastructure  7 major research parks across NC  3 major nonprofit research institutes  108 medical products CRO’s  Active, engaged VC & angel investment  NC Department of Commerce  NC Biotechnology Center  Centers of Innovation: COIN, ibiliti (med tech), Drug Discovery COI  NC Regional Partnerships  Community resources  CED  SBTDC
  15. 15. NC among nano-enabled drug delivery research university leaders 1. University Texas 2. Harvard University 3. MIT 4. University of Michigan 5. Johns Hopkins University 6. University of Illinois 7. Northwestern University 8. University of Washington 9. Purdue University 10. University of Utah 11. Georgia Institute of Technology 12. Washington University 13. University of Florida 14. University Pennsylvania 15. Cornell University 16. University of California at Berkeley 17. University of Massachusetts 18. University of California at San Francisco 19. University of Minnesota 20. NCI 21. Rice University 22. Ohio State University 23. University of California at Los Angeles 24. University of California at Santa Barbara 25. University Nebraska 26. University of North Carolina 27. University of Wisconsin 28. Penn State University 29. Massachusetts General Hospital 30. University of Kentucky 31. Stanford University 32. University of Maryland 33. University of Southern California 34. University of Pittsburgh 35. University of California at Davis 36. Emory University 37. SUNY Buffalo 38. University of California at San Diego 39. Northeastern University 40. Carnegie Mellon University 41. North Carolina State University 42. Vanderbilt University 43. Case Western Reserve University 44. Duke University 45. Brown University 46. CALTECH 47. Arizona State University 48. Columbia University 49. Rutgers State University 50. University of Delaware Source: COIN study (based on publications)
  16. 16. Leading NC nanobio companies  Liquidia: Series B VC funding, entering clinical trials  XinRay: Major partnership with Siemens  Pioneer Surgical Orthobiologics: Product on market  Biodelivery Sciences: Publicly traded; $56.69 MM market cap
  17. 17. COIN will help transform ideas into commercial value. COIN’s role
  18. 18. $$ Develop Demo Quality Concept Plan Design Test LaunchIdea
  19. 19. Burgeoning field with challenges  Shortage of qualified personnel  Education of workforce for future  Limited funding for early-stage innovation  Lack of pre-clinical/clinical testing guidance & facilities  Development of GMP capabilities / manufacturing scale up  Need for more:  Low-cost, flexible research space  Multidisciplinary research partnerships  Business development connections
  20. 20. COIN offers Innovators & entrepreneurs Resources to build relationships crucial for technology translation & business development Industry partners Single point of entry to nanobiotech sectors in NC and access to innovators & entrepreneurs Service providers Resources to develop nanobiotech project pipeline
  21. 21. COIN goals BUILD a community of practice of NC nanobiotech innovators & industry players focused on commercialization CONNECT innovators with promising nanobiotechnology with industry partners, resources, & collaborators GROW nanobiotech infrastructure in NC DRIVE new product development by reducing barriers to commercialization INCREASE the profile of NC nanobiotech activity globally
  22. 22. COIN programs Events & seminars to build, connect, & inform the community:  Nanobiotech Executive Roundtable  Annual NC Nanotech Commercialization Conference: Nanobio track Membership services including knowledge-rich web portal:  Business intelligence  RFP scouting service Innovation services that address specific obstacles to commercialization:  Grant writing  Incubation partners  Connections for pre-clinical testing
  23. 23. NC resources for pre-clinical testing synthesis • WFU Nanotech Center • Nanotech Labs (Yadkinville, NC) Charact erization • WFU Nanotech Center, JSNN, Forsyth Tech, Murdoch In Vitro • Murdoch, Biomedical Innovation Network, JSNN, ECU, RTI In Vivo • Murdoch, Biomedical Innovation Network, JSNN, UNC . RTI Clinical Trials • Duke, UNC, WFU , ECU med schools • RTI, CROs
  24. 24. COIN clients & collaborators  University researchers & tech transfer offices  Pharma/biotech, specialty pharma, drug delivery companies  Startups  VC, angel, & public funding sources  Equipment & software companies  National nanobiotech research institutes  Trade groups  Law & accounting firms  Economic development & policy makers
  25. 25. “…to increase its share of nanotechnology activity nationally and internationally, the (Southeast) region needs to take specific steps in achieving a leadership role…with a focus on improved collaborations and increasing the number and growth of nanotechnology companies.” Working together Source: “Connecting the Dots,” 2006, Southern Growth Policies Board, Georgia Tech, Oak Ridge Nat’l Lab
  26. 26. Creating a Southern nanotechnology strategy  Establish Southern Nanotech Network, a membership network to increase awareness of industry among South’s citizens, governments, & businesses and:  Offer opportunities for collaborative interaction between the public and private sectors  Identify policy advocates  Have each Southern Growth state put advancement of nanotech as a primary economic development goals  Develop/execute branding strategy for Southern nanotech to promote South’s assets within region, nationally & internationally  Coordinate collaborative trips to CA, NY, and MA to promote linkages between region & other major centers  Establish Southern Nanotechnology Institute, based on resources of Oak Ridge & others to:  Develop nanotech business incubation capacity for all Southern states  Increase funding opportunities for Southern institutions including state matching funds for SBIR and other federal grants with specific focus and development of equity funds for nanotech companies  Enhance availability & affordability of research tools  Develop survey of nano-equipment in region’s universities & research labs, so other users may gain access & subsidize their expenses through user agreements  Other considerations  More in-depth look at commercialization including development process, South’s market niches, & role of various funding sources  Explore opportunity/need for equipment cooperatives with vendors Source: “Connecting the Dots,” 2006, Southern Growth Policies Board, Georgia Tech, Oak Ridge Nat’l Lab
  27. 27. Summary  Technology knows no borders  Together we can accelerate commercialization in nanobiotechnology:  Foster nano-size solutions for life science research & medicine for the benefit of mankind  Bridge research community with business & funding sources to create R&D collaborations, new companies, and products
  28. 28. BROOKS ADAMS Executive Director & President brooks.adams@nc-coin.org Cell: 804-363-9574 Assistant: Clare Valcore / 919-782-1991, Ext. 302 1
  29. 29. Addendum
  30. 30. Major categories of nanomaterials Type Definition Example Solid nanoparticles Ultrafine solid particles on nanoscale, including crystals & nanopowders Synthetic bone made from calcium & phosphate particles manipulated at molecular level Hollow nanoparticle Hollow nanoscale particles, including nanotubes & other kinds such as nanohorns & nanocapsules Drug delivery systems or bundle & detonate for cancer detection Nanoscale thin film coatings Coatings with thickness &/or internal structures measured in units of 100 nm or less Antimicrobial coatings applied to surgical dressing or medical devices Nano structured monolithic Bulk solids that have macroscale external dimensions but nanoscale internal structure (could be metal or alloys) High strength medical implants using nanostructured pure titanium Nanocomposites Mixture of 2 or more dissimilar components, at least one of which has nanoscale dimensions Devices with increased responsiveness to pressure for MIS techniques Source: BCC research
  31. 31. Major categories of nanomaterials  Nanotools:  Device enabling viewing/manipulation of nanoscale objects  E.g., scanning probe microscope on market today  Nanodevices  Nanomachines to do useful work in medicine  E.g., nanorobots injected into blood to destroy cancer cells; medical nanosensors incorporating nanoengineered structures, e.g., spintronic sensors that incorporate nanoscale thin films or next generation nanomedical sensors, e.g., respiratory gas sensors (going soon to market) Source: BCC research
  1. A particular slide catching your eye?

    Clipping is a handy way to collect important slides you want to go back to later.

×